logo-loader
RNS
GenIP PLC

Commercial Update

RNS Number : 3790D
GenIP PLC
17 November 2026
 


 

GenIP plc

("GenIP" or the "Company")

 

Commercial Update

 

GenIP plc (AIM: GNIP), a provider of AI-driven services to help research organisations and corporations commercialise their innovations, provides an update on the soft launch of its Invention Evaluator Platform (the “Platform”) as announced on the 19 October 2026.

 

Successful Soft Launch

Several customers have now successfully trialled the Platform and initial feedback has been positive, with customers preferring the Platform’s new features and its streamlined, action-oriented approach to managing and prioritising technologies.

 

During the trial, the Company identified 17 pilot accounts across several international markets and has already begun initial commercial discussions about migrating them to the new Platform including a significant customer from 2025, who has already agreed to initiate the migration plan as an early adopter.

 

Based on this early feedback, management believes the pilot accounts alone could represent a potential annual subscription value of around US$170,000 in aggregate*.

 

Full Commercial Launch Remains on Track

The full commercial launch of the subscription-based Invention Evaluation Platform remains on track for December 2026.

 

Following the full commercial launch, the Company intends to target its historical customer base of approximately 300 customers presenting them the migration path to the subscription model.

 

Given the early feedback and ongoing customer conversations, management now estimates a global total addressable market of approximately US$50million per annum*, before additional services, for the new subscription Invention Evaluation Platform.

 

Continued commercial progress and sales pipeline

GenIP continues to secure orders for its existing services from new and existing customers, including universities in Chile and Brazil, a Brazilian technology company and a Spanish university-industry collaboration network:

  • Following the appointment of a sales representative in Chile, GenIP has secured three new customers and reactivated two historical customer relationships across South America.
  • Increased broader client adoption and repeat usage across academia, government innovation bodies and corporate Research and Development departments, diversifying and strengthening the customer base.
  • Expanded commercial coverage across Asia and Latin America through regional business development appointments.

 

There is also growing engagement from commercial and corporate customers, including opportunities with organisations associated with Saudi Aramco and several advanced proposal discussions with Amazon Web Services (AWS) in Brazil.

 

In aggregate, management estimate these potential customers represent a sales pipeline of approximately US$1.0 million*.

 

 

Outlook

GenIP is entering a new commercial phase, with early positive interest from customers for the Invention Evaluator Platform with its more efficient operating model.

 

The Company’s immediate priorities are now to convert the significant and increasing sales pipeline into confirmed orders, secure its first paid platform subscriptions and demonstrate improved delivery margins.

 

The Board therefore remains confident the business will continue to trade in-line with management expectations for the remainder of 2026 and reduce cash burn by approximately 40% in 2027, as the businesses transitions onto a stronger foundation with significant levels of recurring revenue.

 

* Potential value is not contracted ARR or a revenue forecast.

 

GenIP plc

Melissa Cruz, CEO

Via Walbrook PR

 

 

 

Beaumont Cornish Limited (Nominated Adviser)

Roland Cornish / Asia Szusciak / Andrew Price

Tel: +44 (0) 20 7628 3396

 

 

AlbR Capital Limited (Joint Broker)

Colin Rowbury / Jon Belliss

Tel: +44 (0) 20 7399 9427

cr@albrcapital.com / Jb@albrcapital.com

 

 

Walbrook PR (Financial PR)

Alice Woodings

William Turner

GenIP@walbrookpr.com

Tel: +44 (0) 7407 804 654

Tel: +44 (0) 7407 020 470

 

 

focusIR (Investor Relations)

Kat Perez

Dr Paul Cornelius

GenIP@focusIR.com

Tel: +44 (0) 20 4570 2234

Tel: +44 (0) 20 4570 2246

 

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

 

Distribution: This announcement has been notified via a Regulatory Information Service and it is not authorised for distribution into North America or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of that jurisdiction.

 

About GenIP

GenIP is a next-generation business at the intersection of generative AI and innovation strategy. We empower corporates, venture funds, and research institutions to evaluate, commercialise, and scale breakthrough technologies. By combining proprietary GenAI algorithms with expert human analysis, GenIP delivers decision-grade insights and talent solutions that accelerate innovation outcomes.

 

Service Offerings

GenIP operates through two synergistic service lines:

Service

Description

Value Proposition

 

Invention Intelligence Product Suite

 

AI-powered market intelligence reports assessing the commercial potential of emerging technologies

 

Enables faster, evidence-based decisions on R&D prioritisation, investment, and IP strategy

 

IP Commercialisation Services

End-to-end engagement to help research organisations commercialise innovations

Provides cost-effective, broad support to achieve our clients' strategic objectives

 

Together, these services form a unified GenAI-enabled platform for innovation triage and execution.

 

Vision & Strategy

GenIP aims to become the global leader in generative AI analytics for innovation commercialisation. Our strategy is anchored in three growth pillars:

  • Organic Expansion: Scale Invention Evaluator and Recruitment Services through targeted outreach to corporates, VCs, and research institutions, supported by strategic marketing and digital engagement.
  • Service Deepening: Enhance functionality and margin by expanding GenAI capabilities within both service lines-unlocking new use cases and customer segments.
  • Strategic Acquisitions: Pursue bolt-on acquisitions of complementary GenAI services with validated market traction to broaden our offering and accelerate growth.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDMZMMMVVFGVZM
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

6 min read